title: "Chikungunya Vaccines 2026: IXCHIQ Suspended, VIMKUNYA Approved | Update" date: "2026-04-03" excerpt: "Full update on chikungunya vaccines: FDA suspended IXCHIQ after 1 death and 21 hospitalizations. VIMKUNYA (VLP vaccine) now approved in US, EU, UK. What travelers need to know." category: "vaccines" author: "Mosticare Editorial"

Chikungunya Vaccines: IXCHIQ Suspended, VIMKUNYA Approved -- What to Know

The chikungunya vaccine landscape has undergone a dramatic transformation in the past year. The first-ever approved chikungunya vaccine, IXCHIQ, has been pulled from the US market after serious safety concerns, while a second vaccine, VIMKUNYA, has stepped in with regulatory approvals across multiple major markets. For anyone traveling to or living in chikungunya-endemic regions, understanding these developments is essential.

What Is Chikungunya?

Chikungunya is a viral disease transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes -- the same species that carry dengue and Zika. The disease causes sudden onset of fever and severe joint pain that can be debilitating for weeks or months, and in some cases, years. While rarely fatal in younger adults, chikungunya can cause serious complications in older adults and immunocompromised individuals, including encephalitis.

The disease has spread dramatically in recent decades. The Aedes albopictus mosquito is now established in 16 European countries and 369 regions, up from just 114 regions a decade ago. Local chikungunya transmission has been documented in France, Italy, and Spain, making this no longer solely a tropical concern.

IXCHIQ: The Rise and Fall of the First Chikungunya Vaccine

Initial Approval

IXCHIQ, developed by Valneva Austria GmbH, made history in November 2023 when the US FDA granted it accelerated approval as the first-ever chikungunya vaccine. It was a live attenuated vaccine approved for adults aged 18 and older at increased risk of chikungunya virus exposure.

The approval was celebrated as a landmark moment in neglected tropical disease prevention. However, the accelerated approval pathway meant that ongoing safety monitoring would be critical.

Safety Signals Emerge

By early 2025, postmarketing surveillance began revealing concerning patterns. Reports of serious adverse events accumulated, particularly among older recipients. On May 9, 2025, the FDA and CDC jointly recommended a pause in the use of IXCHIQ for individuals aged 60 and older while investigating postmarketing safety reports.

Full License Suspension

The situation escalated rapidly. On August 6, 2025, the FDA briefly lifted the age-based pause and approved updated labeling. But just two weeks later, on August 22, 2025, the FDA took the extraordinary step of suspending the biologics license entirely.

The safety data that prompted the suspension was stark:

1 death from encephalitis directly attributable to the vaccine, with cerebrospinal fluid PCR testing positive for the vaccine strain of the virus
21 hospitalizations reported among vaccine recipients
3 total deaths reported among serious adverse event cases
Multiple reports of chikungunya-like illness consistent with vaccine-strain disease

The suspension letter from the FDA effectively halted all distribution and administration of IXCHIQ in the United States.

Analysis and Implications

A Health Affairs analysis examined whether vaccine license suspensions like IXCHIQ's represent outliers or a new regulatory normal. Meanwhile, a Lancet Infectious Diseases commentary called for more transparency about the data underpinning the FDA's decision.

The IXCHIQ experience underscores a fundamental tension in vaccine development: the live attenuated approach that produces strong immune responses can also carry risks, particularly when the vaccine virus retains the capacity to cause disease-like symptoms in vulnerable populations.

VIMKUNYA: The New Standard in Chikungunya Prevention

What Is VIMKUNYA?

VIMKUNYA, developed by Bavarian Nordic, takes a fundamentally different approach from IXCHIQ. Rather than using a live attenuated virus, VIMKUNYA is a virus-like particle (VLP) vaccine. VLPs mimic the structure of the chikungunya virus but contain no viral genetic material, making them incapable of causing infection or disease. This approach offers a significantly different safety profile compared to live attenuated vaccines.

Regulatory Approvals

VIMKUNYA has achieved regulatory approvals across three major markets:

United States: FDA approved February 14, 2025, for individuals aged 12 years and older
European Union: European Commission approval in February 2025
United Kingdom: Approval granted, marking the third major regulatory milestone

In April 2025, the US Advisory Committee on Immunization Practices (ACIP) approved recommendations for VIMKUNYA's use in US travelers and laboratory workers at risk of chikungunya exposure.

Clinical Data

VIMKUNYA demonstrated strong immunogenicity in clinical trials, generating robust neutralizing antibody responses against chikungunya virus. The FDA's regulatory review confirmed a favorable benefit-risk profile for the approved population.

Post-authorization safety monitoring through August 2025 has been documented in the literature, providing early real-world safety data that supports the clinical trial findings.

Availability and Commercial Launch

Bavarian Nordic has moved aggressively to make VIMKUNYA available globally. In October 2025, the vaccine was launched commercially in Sweden, Norway, Finland, Italy, and Spain -- markets where the expanding range of Aedes albopictus makes chikungunya a growing concern.

A submission to Health Canada was underway as of early 2026, with potential approval expected in the first half of 2026. VIMKUNYA generated approximately $13.4 million in revenue during 2025, its first partial year on the market.

Dosing and Target Population

VIMKUNYA is indicated for individuals 12 years of age and older at risk of chikungunya exposure. The recommended dosing schedule is designed for practical deployment in travel medicine settings.

IXCHIQ vs. VIMKUNYA: Key Differences

| Feature | IXCHIQ | VIMKUNYA | |---|---|---| | Manufacturer | Valneva | Bavarian Nordic | | Vaccine type | Live attenuated | Virus-like particle (VLP) | | Age indication | 18+ years | 12+ years | | Current status | License suspended (US) | Approved (US, EU, UK) | | Key safety concern | Vaccine-strain encephalitis | Standard VLP profile | | Viral replication | Yes | No | | Doses | Single dose | As recommended |

The most critical difference is in the underlying technology. IXCHIQ's live attenuated approach meant the vaccine virus could replicate in recipients, which in rare cases led to vaccine-strain disease. VIMKUNYA's VLP technology eliminates this risk entirely because virus-like particles cannot replicate.

What This Means for Travelers in 2026

If You Were Previously Vaccinated with IXCHIQ

If you received IXCHIQ before the suspension, the FDA recommends monitoring for symptoms of chikungunya-like illness, particularly joint pain, fever, and headache. Contact your healthcare provider if you develop neurological symptoms such as confusion, severe headache, or neck stiffness. There is no recommendation to receive VIMKUNYA after prior IXCHIQ vaccination without medical consultation.

If You Are Planning Travel to Endemic Regions

VIMKUNYA is now the only chikungunya vaccine available in the US, EU, and UK. It is recommended for travelers heading to regions where chikungunya is actively circulating, including parts of South and Southeast Asia, sub-Saharan Africa, and the Americas. Consult a travel medicine specialist well before your departure date.

Regions of Concern in Europe

With Aedes albopictus now established across southern Europe and expanding northward, the risk of locally acquired chikungunya in Europe is real and growing. Italy, France, and Spain have all experienced local transmission events in recent years. While vaccination is not routinely recommended for European residents, those living in high-risk areas or spending extended time outdoors during peak mosquito season should discuss vaccination with their physician.

Physical Protection Remains Essential

No chikungunya vaccine provides 100% protection, and vaccines are not available for children under 12. Physical mosquito bite prevention remains a critical layer of defense, particularly for:

Children under 12 who are not eligible for VIMKUNYA
Individuals who cannot receive vaccines due to medical contraindications
Travelers to areas where multiple mosquito-borne diseases co-circulate
Anyone during the period before vaccine-induced immunity develops

Effective physical protection includes DEET-based repellents, permethrin-treated clothing, bed nets, and maintaining screened environments -- measures that protect against all mosquito-borne diseases simultaneously, not just chikungunya.

Looking Ahead

The chikungunya vaccine story is far from over. The rapid sequence of IXCHIQ's approval, safety crisis, and suspension -- followed by VIMKUNYA's approval -- illustrates both the promise and complexity of developing vaccines for neglected tropical diseases. As chikungunya continues to expand its geographic range, having a safe and effective vaccine available is more important than ever.

For the latest chikungunya vaccine availability in your region, consult your national health authority or a travel medicine clinic.